Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 14/20 | 0.38 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.36 |
| ▸ | MAG | P20916 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341461 | 0.97 | CD22 (0.39) | CD22NANPMAG | |
| SCHEMBL13402333 | 0.91 | CD22 (0.38) | CD22NANP | |
| SCHEMBL14454530 | 0.90 | NANP (0.43) | CD22NANP | |
| SCHEMBL13948848 | 0.89 | CD22 (0.36) | CD22 | |
| SCHEMBL13948845 | 0.89 | CD22 (0.34) | CD22NANPMAG | |
| SCHEMBL12341459 | 0.88 | NANP (0.39) | CD22NANPMAG | |
| SCHEMBL13948842 | 0.88 | CD22 (0.37) | CD22NANP | |
| SCHEMBL13402336 | 0.86 | CD22 (0.37) | CD22NANP | |
| SCHEMBL12341474 | 0.86 | CD22 (0.37) | CD22 | |
| SCHEMBL12341465 | 0.85 | CD22 (0.35) | CD22NANPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187546-B2 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-04-01 | — | — | US | disclosed |
| US-20100041872-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20090305967-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| US-20090124544-A1 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF PROTEASE RESISTANT HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | NEOSE TECHNOLOGIES ,INC. A DELAWARE CORPORATION | 2009-05-14 | — | — | US | disclosed |
| US-20090028822-A1 | Glycopegylated Interferon Alpha | NEOSE TECHNOLOGIES, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080300173-A1 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] | NOVO NORDISK A/S (DK) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028822-A1 | Glycopegylated Interferon Alpha | IFNG, IFNAR1, OGT | CD22 383/4885NANP 366/4885MAG 924/4885 |
| US-20090305967-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | F7, F13B, F13A1 | CD22 1638/4885NANP 431/4885MAG 576/4885 |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | CD22 390/4885NANP 156/4885MAG 194/4885 |
| US-20080300173-A1 | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] | GLP1R, GIPR, IAPP | CD22 433/4885NANP 896/4885MAG 736/4885 |
| US-20100041872-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | CD22 367/4885NANP 306/4885MAG 119/4885 |
| US-20090124544-A1 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF PROTEASE RESISTANT HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS | GHITM, PTMS, GHRHR | CD22 2233/4885NANP 386/4885MAG 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.